Support our Foundation of Myology project
1722 news items
A meta-analysis of the efficacy and safety of the onasemnogen abeparvovec in SMA
On 26/06/2024
Brazilian researchers have compiled data from the literature on one of three innovative drugs designed to treat children with type 1 spinal muscular atrophy (SMA1).…
European recommendations for the treatment of epilepsy in mitochondrial diseases
On 25/06/2024
A group of 24 experts (two of whom practice in France), members of five European reference networks, used the Delphi method to draw up recommendations…
Improved pneumococcal vaccination coverage in inflammatory diseases in the United States
On 25/06/2024
Faced with very low vaccination coverage rates, particularly against pneumococcus, in patients with inflammatory pathologies, American clinicians set up an action plan: the target population…
Normal strength is not essential for a functional hand – Interview with Valérie Decostre
On 24/06/2024
Valérie Decostre is a physiotherapist and researcher at the Neuromuscular Physiology and Evaluation Laboratory, directed by Jean-Yves Hogrel, at the Neuromuscular Investigation Center of the…
Nusinersen does not prevent hip instability in SMA type II
On 24/06/2024
Researchers in Hong Kong investigated the extent to which treatment with intrathecal nusinersen influenced the risk of bilateral hip dislocation, a complication very frequently observed…
Cardiac myosin inhibitor improves skeletal muscle contractility in Laing myopathy
On 24/06/2024
Mavacamten is a small molecule inhibitor of myosin ATPase activity, used in hypertrophic cardiomyopathies, which targets myocardial hypercontractility by reducing the number of myosin heads…
Gait in DMD now easier to analyze in real life
On 21/06/2024
Californian researchers have developed an original, easy-to-use method for measuring gait parameters in young patients with Duchenne muscular dystrophy (DMD): a gyroscope contained in a…
An indirect comparison of two innovative compounds in the treatment of myasthenia gravis
On 21/06/2024
Efgartigimod (Vyvgart®) and ravulizumab (Ultomiris®) are two new-generation monoclonal antibodies, anti-FcRN and anti-C5 respectively, designed to treat refractory forms of generalised autoimmune myasthenia with positive…
ERN EURO-NMD webinar, 27 June: Prof. Dr. Jan Kirschner (Germany)
On 20/06/2024
Genetic therapies and therapy developments for SMA Thursady 27 June 2024, 16:00 – 17:00 Paris time Prof. Dr. Jan Kirschner (Medical Center – University of Freiburg,…
Belgian recommendations for the management of myasthenia gravis
On 20/06/2024
Following the sharing of experience in the field, and in view of the very rapid development of innovative therapies, Belgian clinicians have drawn up national…
M&M’s – Muscle Monday Seminar – 24 June – Kay Ohlendieck (Ireland)
On 19/06/2024
Proteomic tissue and biofluid markers of dystrophinopathy Monday 24 June – 12am – Institute of Myology, Paris Pr Kay Ohlendieck (Maynooth University, Ireland) More information…
Successful use of CAR-T cells in simultaneous myasthenia gravis and Lambert-Eaton syndrome
On 19/06/2024
A German team has reported the treatment with autologous anti-CD19 CAR-T cells of two women with both autoimmune myasthenia and Lambert-Eaton syndrome who had failed…
DMD and rhabdomyosarcoma share similarities
On 19/06/2024
Canadian researchers have written a book chapter summing up the knowledge acquired in the field of muscle stem cells (also known as satellite cells): these…
SNOW-P: an Australian programme to manage eating behaviours in DMD
On 18/06/2024
The SNOW-P programme, which stands for Supporting Nutrition and Optimising Wellbeing Programme, was co-constructed with carers of young boys with Duchenne muscular dystrophy. Fifty-three of…
A remote study of the validity of the North Star functional scale
On 18/06/2024
The COVID-19 pandemic provided an opportunity to rethink the methods used to assess functional scores in neuromuscular patients, particularly those with Duchenne muscular dystrophy (DMD):…
Omega3s appear to improve the FOXP3 regeneration biomarker in DMD
On 17/06/2024
Supplementation with long-chain omega-3 polyunsaturated fatty acids (ω-3 LCPUFA) was tested in a double-blind, placebo-controlled study for six months in 31 boys with Duchenne muscular…
Myasthenia gravis: mycophenolate and methotrexate better tolerated than azathioprine
On 17/06/2024
A UK national survey of 235 people with myasthenia gravis, 166 on azathioprine, 102 on mycophenolate and 40 on methotrexate, showed that : the most…
An early marker of myocardial damage in DMD
On 17/06/2024
Catalan clinicians have studied the possibility of early detection of myocardial alterations in Duchenne muscular dystrophy (DMD): 23 adolescents with dystrophinopathy (14 DMD, 8 Becker,…
Expert consensus on the assessment and management of adverse reactions to delandistrogene moxeparvovec (Elevidys®)
On 14/06/2024
Given the rapid and recent development of microdystrophin gene therapy treatments for Duchenne muscular dystrophy (DMD), there is little data on the side effects of…
ENMC workshop rethinks diagnosis and clinical trial design in inclusion myositis
On 14/06/2024
Ten years after the publication of the diagnostic criteria for inclusion myositis, an international group of around thirty experts (including two from France) took part…
